研究人员发现了包括 CXCR4-S1P 1 在内的多种 G 蛋白偶联受体（GPCR）异源二聚体。在过表达相关受体的 HEK293A 细胞中，BiFC 实验显示 CXCR4 与 S1P 1 可形成异源二聚体；PLA 实验进一步证实了二者的特异性相互作用，且排除了非选择性聚集的可能；定量 BRET 实验则从定量 ...

异源二聚体的鉴定与验证：通过基于 BiFC 实验的高通量筛选，研究人员发现了包括 CXCR4-S1P?在内的多种 G 蛋白偶联受体（GPCR）异源二聚体。在过表达相关受体的 HEK293A 细胞中，BiFC 实验显示 CXCR4 与 S1P?可形成异源二聚体；PLA 实验进一步证实了二者的特异性相互 ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...

In December of last year, GPCR USA presented results at the American Society of Hematology conference evaluating the impact of inhibiting CXCR4 and ADRB2 (beta-2 adrenergic receptor) on stem cell ...

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a ...

2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.

Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s ...